India, June 17 -- Shares of Agios Pharmaceuticals Inc. (AGIO) have retreated approximately 43% from their 52-week high of $62.58, reported last November, and trade near the $35 level.
The company's flagship drug, PYRUKYND, has demonstrated strong year-over-year sales growth since its initial approval in February 2022. The drug is currently indicated for the treatment of hemolytic anemia in adults with pyruvate kinase deficiency.
Pyruvate kinase (PK) deficiency is a rare disease caused by inherited mutations in the PKLR gene, resulting in impaired cellular energy production and reduced red blood cell survival. People with PK deficiency can experience a range of signs and symptoms, including anemia, debilitating fatigue, exercise intoleranc...